Correlation Between CD133+ Stem Cells and Clinical Improvement in Patients with Autism Spectrum Disorders Treated with Intrathecal Bone Marrow-derived Mononuclear Cells

Autor: Villarreal-Martinez, Laura, MartÍnez-Garza, Laura Elia, Rodriguez-Sanchez, Iram Pablo, Alvarez-Villalobos, Neri, Guzman-Gallardo, Fernando, Pope-Salazar, Sulia, Salinas-Silva, Cynthia, Cepeda-Cepeda, Maria Guadalupe, Garza-Bedolla, Alejandra, Dominguez-Varela, Irving Armando, Villarreal-Martinez, Daniel Zacarias, Treviño-Villarreal, Jose Humberto, Gomez-Almaguer, David
Jazyk: angličtina
Rok vydání: 2022
Předmět:
Zdroj: Innov Clin Neurosci
Popis: Autism spectrum disorders (ASDs) are a group of neurodevelopmental pathologies characterized by social and communication deficits, for which treatments are limited. Cell therapies, including intrathecal (IT) administration of bone marrow (BM) mononuclear cells (BM-MNC), improves symptoms in patients with ASD. Twenty-four patients diagnosed with ASD, according to the Diagnostic and Statistical Manual of Mental Disorders Text Revision Fourth Edition (DSM-IV-TR) criteria, were autologously treated with IT BM-MNC, and the clinical effect was evaluated using the Childhood Autism Rating Scale (CARS) on Days 30 (n=24) and 180 (n=14) post-treatment. IT BM-MNC improved clinical outcomes by Day 30 (p=0.0039), and those benefits remained and were further accentuated by Day 180 post-treatment (n=14; p=
Databáze: OpenAIRE